Merck on Wednesday announced that FDA has granted priority review status to its experimental integrase inhibitor raltegravir, Reuters Health reports. According to Reuters Health, the agency will review Merck’s application within six months rather than the standard 10 to 12 months (Reuters Health, 6/27). [click link for full article]
More: continued here